Who's who

3 Houston innovators to know this week

From leading OTC or the TMC to the future of recycling — here's who's having a busy week in innovation. Courtesy photos

May in Houston is starting off right with the Offshore Technology conference making its home in NRG Park all this week. There's thousands of business men and women in town for the events — if you're among them, check out these can't miss innovation-related events at OTC. OTC aside, big things are happening in the Texas Medical Center as well as in electronics manufacturing. Here's which Houston innovators to keep an eye on this week.

Wafik Beydoun, chairman of the board of OTC

Wafik Beydoun has served on the board of OTC for almost a decade. Courtesy of Beydoun

It's the 50th year for the Houston-based Offshore Technology Conference — which starts today — to take over the town, and it's Wafik Beydoun's last event as chairman of the board. He's been involved with the organization for almost a decade and he's seen the technology evolve in the industry and at OTC.

"The rising tide of the digital revolution is lifting us all — not only OTC or the industry — and it's lifting us at an exponential rate," Beydoun tells InnovationMap. "Digital is moving now exponentially, whether we want it to or not, we're benefitting from it." Read the full Q&A with Beydoun here.

Kelly Hess, CEO of CompuCycle

Kelly Hess leads CompuCycle, a Houston-based company focused on electronics recycling. Courtesy of CompuCycle

The game is forever changed for Kelly Hess. CompuCycle is her electronics recycling company she leads as CEO with her husband, Clive, who is executive vice president of the company. The company just got a major addition to its team: a electronics shredder that can process 40,000 pounds daily of parts from machines that can't be refurbished. The new shredder is the only of its kind in Houston and is perfectly timed for the company, following a 2018 Chinese law.

"China is no longer accepting scrap, which is where a lot of materials would go after it was dismantled," Kelly says. "That's why we've created this solution to be able to responsibly handle it here in the U.S." Read more about CompuCycle and where recycling is headed.

Bill McKeon, CEO of the Texas Medical Center

TMC has revealed renderings and new details about the new TMC3 campus. Photo via tmc.edu

Bill McKeon might be one of the busiest businessmen in town. He's leading the largest medical center in the world, while simultaneously building it even bigger. The Texas Medical Center — along with the other institutional partners — released new renderings and details about the TMC3 campus.

"Texas Medical Center is eager to move forward with a bold, imaginative and dynamic new design vision for the TMC3 Master Plan," says TMC CEO and president, Bill McKeon, in a press release. "With the combined talents of Elkus Manfredi Architects, Transwestern, and Vaughn Construction on-board, I couldn't be more confident that this dream team will flawlessly execute the totality of the project's vision and fulfill its mission to bring together leading researchers and top-tiered expertise from the private sector to create the number one biotechnology and bioscience innovation center in the entire world." Click here to check out the renderings and read the full story.Click here to check out the renderings and read the full story.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News